What is MyTide?
MyTide Therapeutics, based in Boston, MA, is a pioneering company operating at the intersection of peptide and biopolymer manufacturing and computational biology. The company is dedicated to overcoming the inherent time and labor constraints in traditional chemical and screening processes that hinder the clinical translation of innovative therapeutics. By leveraging its proprietary quick-turn manufacturing technology and advanced AI-driven predictive analytics, MyTide unlocks access to a novel peptide space, facilitating the discovery and therapeutic manufacturing of difficult-to-synthesize natural and non-natural peptides and peptide conjugates. Their focus spans critical therapeutic areas including metabolic conditions, oncology, inflammatory disorders, and infectious diseases, aiming to accelerate the development of life-saving treatments.
How much funding has MyTide raised?
MyTide has raised a total of $7M across 1 funding round:
Series A
$7M
Series A (2022): $7M with participation from Alloy Therapeutics and Uncommon Denominator
Key Investors in MyTide
Alloy Therapeutics
Alloy Therapeutics is a biotechnology company that provides advanced technologies and services to support the discovery and development of new medicines. The company collaborates with academic, biotech, and pharmaceutical partners to develop biologics such as antibodies, genetic medicines, and cell therapies.
Uncommon Denominator
Uncommon Denominator is an early stage venture capital firm that invests in consumer brands, software companies, and frontier technologies with a unique skill-spike in a key area. They focus on technology-enabled consumer brands that resonate psychologically, as well as SaaS companies that help businesses save or earn money. The firm seeks to back companies that are exceptionally skilled in their niche rather than just meeting standard business criteria. Their investment strategy emphasizes authenticity and impactful marketing in the consumer sector.
What's next for MyTide?
With the recent major strategic investment, MyTide Therapeutics is poised for accelerated growth and enhanced research and development capabilities. This significant capital infusion is expected to fuel the expansion of its manufacturing capacity and further refine its AI-powered computational biology platform. The company's strategic focus on streamlining therapeutic translation, particularly in challenging peptide synthesis, positions it to address unmet needs across a spectrum of serious diseases. Future endeavors will likely involve scaling operations to meet growing demand, forging new strategic partnerships within the biopharmaceutical ecosystem, and advancing its pipeline of novel peptide-based therapeutics toward clinical trials.
See full MyTide company page
